ABOUT VOYAGEUR
Voyageur Pharmaceuticals Ltd. is a drug manufacturing company focused on radiographic contrast media products. Voyageur is developing barium and iodine generic radiographic drugs, for the healthcare market. Voyageur is unique, as it is sourcing its own main ingredients from its own mineral deposits. Voyageur is building a business model that will allow it to be a fully integrated company in the radiographic market place.
Near-term cash flow is expected to be achieved through third party pharmaceutical manufacturing, sourcing third party minerals, turn key manufacturing, bottling and distribution of barium and iodine radiographic pharmaceutical drugs for MRI, X-ray and CT scan applications.
By implementing our “From The Earth to The Bottle” strategy, Voyageur will have a competitive advantage, by having low ingredient costs for our pharmaceutical product line.
Investor Intel-Voyageur Milestones
https://investorintel.com/markets/biotech-healthcare/biotech-intel/voyageur-pharmaceuticals-completes-fda-submission-milestone-for-first-barium-contrast-product-license-application/
Voyageur Pharmaceuticals Completes Milestone with the FDA and Continues to Move Towards Commercialization on Three Fronts
Voyageur Pharmaceuticals FDA-Progress May 18 2022
Buy rating increased to $0.55/share- Fundamental Research Corp
Voyageur-Mar-2022-Update
Global Contrast Media Shortages at Critical State
https://www.yicaiglobal.com/news/ge-healthcare-shanghai-contrast-media-plant-scrambles-to-end-global-shortage
North American Contrast Drug Shortage- Highlights Importance Of Full Integration. Voyageur is creating solutions to the reliance on foreign produced drugs.
https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Contrast-Media-Shortage-
Voyageur Pharmaceuticals’ X-Ray Contrast Media Provides a Dramatic Increase in Valuation
https://investorintel.com/markets/biotech-healthcare/biotech-intel/voyageur-pharmaceuticals-x-ray-contrast-media-provides-a-dramatic-increase-in-valuation/